

Dr Santiago Ponce-Aix - SCLC Post Progression Therapy Options



These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch Dr Santiago Ponce-Aix outline SCLC post-progression therapy options.

[CLICK TO DOWNLOAD
WEBINAR TRANSCRIPT](#)

SCLC Webinar Chapters

Introduction for Dr Ponce-Aix

New Standard of Care for ES-SCLC

Retreatment with Platinum as 2nd line (>90 days)

Immunotherapy in 2nd line

Biomarker Selection

Lurbinectedin Basket Trial Data

ATLANTIS Trial

RESILIENT Trial

Lurbinectedin plus Irinotecan

Lurbinectedin plus Atezolizumab

Summary

ZEPZELCA[®] is a registered trademark of PharmaMar SA. ZEPZELCA[®] is under license from PharmaMar SA.